Grants.govNational Institutes of Health

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

Posted Nov 18, 2024·open

AGENCY

HHS-NIH11

PROGRAM

Discretionary

AMOUNT

—

CLOSES

Jan 7, 2027

Apply on Grants.gov ↗More info from funder ↗

Description

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Eligibility

Special district governments; City or township governments; Independent school districts; Private institutions of higher education; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Public and State controlled institutions of higher education; County governments; Native American tribal organizations (other than Federally recognized tribal governments); Native American tribal governments (Federally recognized); For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

Contact

National Institutes of Health

grantsinfo@nih.gov

301-402-2541

Additional details

Funding instrument: Grant
Cost sharing required: No
Archived: Feb 12, 2027

Opportunity number: PAR-25-070

Search this number on Grants.gov for the official listing.